Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M McGuire

Showing results (551-560 of 568) with videos related to

Pageof 57
Sort By:
Frontiers in Cardiovascular Medicine|January 31, 2022
Trpc6 Promotes Doxorubicin-Induced Cardiomyopathy in Male Mice With Pleiotropic Differences Between Males and FemalesNadine Norton, Katelyn A Bruno, Damian N Di Florio, et al.
Journal of Medicinal Chemistry|June 30, 2012
(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritisAlexander G Dossetter, Howard Beeley, Jonathan Bowyer, et al.
Journal of Medicinal Chemistry|April 24, 2018
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one)Kurt G Pike, Bernard Barlaam, Elaine Cadogan, et al.
Bioorganic & Medicinal Chemistry Letters|October 3, 2009
5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymeraseDavid A Ellis, Julie K Blazel, Chinh V Tran, et al.
Annals of Surgery|April 15, 2004
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failureAchilles A Demetriou, Robert S Brown, Ronald W Busuttil, et al.
Bioorganic & Medicinal Chemistry Letters|July 30, 2008
4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymeraseDavid A Ellis, Julie K Blazel, Stephen E Webber, et al.
The Journal of Pediatrics|June 2, 2006
Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study groupRobert H Squires, Benjamin L Shneider, John Bucuvalas, et al.
Journal of Medicinal Chemistry|October 14, 2021
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target EngagementBernard Barlaam, Chris De Savi, Allan Dishington, et al.
Plos Pathogens|July 24, 2025
Effect of obesity on the acute response to SARS-CoV-2 infection and development of post-acute sequelae of COVID-19 (PASC) in nonhuman primatesKristin A Sauter, Gabriela M Webb, Lindsay Bader, et al.
ACS Medicinal Chemistry Letters|March 28, 2015
Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacologyJeffrey W Johannes, Lynsie Almeida, Bernard Barlaam, et al.
Pageof 57

Showing results (551-560 of 568) with videos related to

Sort By:
Pageof 57
Frontiers in Cardiovascular Medicine|January 31, 2022
Trpc6 Promotes Doxorubicin-Induced Cardiomyopathy in Male Mice With Pleiotropic Differences Between Males and FemalesNadine Norton, Katelyn A Bruno, Damian N Di Florio, et al.
Journal of Medicinal Chemistry|June 30, 2012
(1R,2R)-N-(1-cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3-b]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritisAlexander G Dossetter, Howard Beeley, Jonathan Bowyer, et al.
Journal of Medicinal Chemistry|April 24, 2018
The Identification of Potent, Selective, and Orally Available Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase: The Discovery of AZD0156 (8-{6-[3-(Dimethylamino)propoxy]pyridin-3-yl}-3-methyl-1-(tetrahydro-2 H-pyran-4-yl)-1,3-dihydro-2 H-imidazo[4,5- c]quinolin-2-one)Kurt G Pike, Bernard Barlaam, Elaine Cadogan, et al.
Bioorganic & Medicinal Chemistry Letters|October 3, 2009
5,5'- and 6,6'-dialkyl-5,6-dihydro-1H-pyridin-2-ones as potent inhibitors of HCV NS5B polymeraseDavid A Ellis, Julie K Blazel, Chinh V Tran, et al.
Annals of Surgery|April 15, 2004
Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failureAchilles A Demetriou, Robert S Brown, Ronald W Busuttil, et al.
Bioorganic & Medicinal Chemistry Letters|July 30, 2008
4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymeraseDavid A Ellis, Julie K Blazel, Stephen E Webber, et al.
The Journal of Pediatrics|June 2, 2006
Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study groupRobert H Squires, Benjamin L Shneider, John Bucuvalas, et al.
Journal of Medicinal Chemistry|October 14, 2021
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target EngagementBernard Barlaam, Chris De Savi, Allan Dishington, et al.
Plos Pathogens|July 24, 2025
Effect of obesity on the acute response to SARS-CoV-2 infection and development of post-acute sequelae of COVID-19 (PASC) in nonhuman primatesKristin A Sauter, Gabriela M Webb, Lindsay Bader, et al.
ACS Medicinal Chemistry Letters|March 28, 2015
Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacologyJeffrey W Johannes, Lynsie Almeida, Bernard Barlaam, et al.
Pageof 57